Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Greece

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

- PMLiVE

Novartis signs $500m immuno-oncology deal

Gains access to Xoma's TGFb antibody programme

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

- PMLiVE

Pricing of Novartis’ Entresto about right, concludes ICER

Supports potential for $5bn-a-year brand 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links